A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris

Main Article Content

VP Werth
Perelman School of Medicine, University of Pennsylvania and Corporal Michael J. Crescent VAMC, Philadelphia, PA

P Joly
Department of Dermatology, Rouen University Hospital and INSERm 1234, Rouen

D Mimouni
Sackler School of Medicine, Tel Aviv University, Tel Aviv and Rabin Medical Center, Petah-Tikva

E Maverakis
Department of Dermatology, University of California Davis School of Medicine, Sacramento, CA

P Lahane
Roche Products, Ltd., Welwyn Garden City

L Gearhart
F. Hoffmann La-Roche, Basel

P Pordeli
Roche Products, Ltd., Mississauga, ON

DM Chen
Genentech, Inc, South San Fransisco, CA

Keywords

Pemphigus Vulgaris, Rituximab, Mycophenolate Mofetil

Abstract

Abstract not available.

References

1. Murrell DF, et al. J Am Acad Dermatol. 2018 Feb 10 [Epub ahead of print]
2. Rituxan (rituximab) [prescribing information]. Genentech, Inc., 2019.
3. MabThera (rituximab) [summary of product characteristics]. Roche, 2019.
4. Joly P, et al. Lancet. 2017;389:2031-2040
5. Chen DM, et al. British J Dermatol. 2019 Sep 5. [Epub ahead of print]
6. Beissert S, et al. J Invest Dermatol. 2010;130:2041-2048.
7. Boulard C, et al. Br J Dermatol 2016;175:142-149.

Article Sidebar

Poster PDF
Published
Jan 28, 2020

Article Details

How to Cite
[1]
Werth, V., Joly, P., Mimouni, D., Maverakis, E., Lahane, P., Gearhart, L., Pordeli, P. and Chen, D. 2020. A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris. SKIN The Journal of Cutaneous Medicine. 4, 1 (Jan. 2020), S26.
Issue
Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Section
Bullous Disease
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.